BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu X, Zhou XQ, Shang XW, Wang L, Li Y, Yuan H, Hu FQ. Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment. J Zhejiang Univ Sci B 2020;21:218-33. [PMID: 32133799 DOI: 10.1631/jzus.B1900468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Paskeh MDA, Saebfar H, Mahabady MK, Orouei S, Hushmandi K, Entezari M, Hashemi M, Aref AR, Hamblin MR, Ang HL, Kumar AP, Zarrabi A, Samarghandian S. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yuan R, Fan Q, Liang X, Han S, He J, Wang Q, Gao H, Feng Y, Yang S. Cucurbitacin B inhibits TGF-β1-induced epithelial–mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways. Chin Med 2022;17. [DOI: 10.1186/s13020-022-00581-z] [Reference Citation Analysis]
3 Liu X, Zhou X, Shang X, Wang L, Li Y, Yuan H, Hu F. Erratum to: Inhibition of chemotherapy-related breast tumor EMT by application of redox-sensitive siRNA delivery system CSO-ss-SA/siRNA along with doxorubicin treatment. J Zhejiang Univ Sci B 2022;23:171-2. [PMID: 35187891 DOI: 10.1631/jzus.B19e0468] [Reference Citation Analysis]
4 Guo K, Feng Y, Zheng X, Sun L, Wasan HS, Ruan S, Shen M. Resveratrol and Its Analogs: Potent Agents to Reverse Epithelial-to-Mesenchymal Transition in Tumors. Front Oncol 2021;11:644134. [PMID: 33937049 DOI: 10.3389/fonc.2021.644134] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Jaiswal S, Dutta P, Kumar S, Chawla R. Chitosan modified by organo-functionalities as an efficient nanoplatform for anti-cancer drug delivery process. Journal of Drug Delivery Science and Technology 2021;62:102407. [DOI: 10.1016/j.jddst.2021.102407] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Ashrafizadeh M, Zarrabi A, Hushmandi K, Hashemi F, Rahmani Moghadam E, Raei M, Kalantari M, Tavakol S, Mohammadinejad R, Najafi M, Tay FR, Makvandi P. Progress in Natural Compounds/siRNA Co-delivery Employing Nanovehicles for Cancer Therapy. ACS Comb Sci 2020;22:669-700. [PMID: 33095554 DOI: 10.1021/acscombsci.0c00099] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 16.5] [Reference Citation Analysis]